Biomerica Approved for Listing on the Nasdaq Capital Market
Company to Begin Trading on Nasdaq on August 26, 2016: Shares Will Trade as BMRA IRVINE, CA–(Marketwired – August 24, 2016) – Biomerica Inc. (OTCQB: BMRA) today announced […]
About Marketwired
This author has not written his bio yet.
But we are proud to say that Marketwired contributed 101 entries already.
Entries by Marketwired
Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
Theratechnologies Inc. announces that it has been notified by its partner, TaiMed Biologics Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).
OCHWW to Host “Inaugural Electronic Health Records Apex”
Ogilvy CommonHealth Worldwide’s Invitation-Only Conference Will Be Held at the Network’s NJ-Based Headquarters in May.
LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer
LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer Bringing the Total Raised for the Current Class of 4Catalyzer Companies to a Quarter-Billion […]
Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition
Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call […]
Physicians and Patients Need Comparative Effectiveness Studies That Target Specific Treatment Pathways, According to Cutting Edge Information
RESEARCH TRIANGLE PARK, NC–(Marketwired – August 25, 2015) – New research from pharmaceutical intelligence firm Cutting Edge Information shows that patients and physicians are looking for targeted comparative effectiveness data […]
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination […]
Corbus Pharmaceuticals’ Investigational Drug Resunab Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
NORWOOD, MA–(Marketwired – Aug 19, 2015) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and […]
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box Technology
BONITA, CA–(Marketwired – August 17, 2015) – PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the […]
FDA Grants Fast Track Designation to ContraFect’s CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA
YONKERS, NY–(Marketwired – Aug 17, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody […]